COMP <GO>
GSK vs SNY // RSI-14 & 200D SMA MOMENTUM
GSK plc American (NYSE) VS. Sanofi ADS (NASDAQ) • 15-METRIC TALLY: GSK 2
— SNY 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: SNY
LAST: $49.51 (+1.71%) • MKT CAP: $98.47B
rsi-technicals
46.8
LAST: $44.34 (+2.81%) • MKT CAP: $105.19B
rsi-technicals
58.8
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (GSK VS. SNY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | GSK | SNY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.90% | 9.90% | 0.00 | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | 21.0x | 21.0x | 0.00 | TIE | /valuation <GO> |
| Free Cash Flow Yield | 2.21% | 2.21% | 0.00 | TIE | /fcf-yield <GO> |
| Operating Margin | 13.90% | 13.90% | 0.00 | TIE | /operating-margins <GO> |
| Net Profit Margin | 10.90% | 10.90% | 0.00 | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 8.80% | -1.10% | +9.90 | GSK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.74 | 3.74 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | GSK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 46.8 | 58.8 | -12.00 | SNY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.95 | 1.14 | -0.19 | SNY | /macro-sensitivity <GO> |
| Forward P/E Multiple | 30.5x | 30.5x | 0.00 | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $98.47B | $105.19B | -$6.72B | SNY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | GSK REV | SNY REV | GSK GROSS % | SNY GROSS % | GSK FCF | SNY FCF |
|---|---|---|---|---|---|---|
| INSPECT INDIVIDUAL XBRL MODELS AT GSK FA <GO> AND SNY FA <GO>. | ||||||
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
GSK // BETA 0.95
SNY // BETA 1.14